---
category: news
title: "Kiromic Announces FDA IND Submission First-In-Human, AI derived Off-The-Shelf IsoMesothelin Gamma Delta CAR T-cell Therapy, 30 Days Before the End of the Second Quarter"
excerpt: "Kiromic achieves key milestone for this first-in-human Phase 1 clinical trial with a target derived by Kiromicâ€™s AI platform. HOUSTON-- ( BUSINESS WIRE )--Kiromic Biopharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company with a proprietary artificial intelligence neural network platform (Diamond AI) that is used to develop novel oncology therapeutics,"
publishedDateTime: 2021-05-24T15:55:00Z
originalUrl: "https://www.businesswire.com/news/home/20210524005256/en/Kiromic-Announces-FDA-IND-Submission-First-In-Human-AI-derived-Off-The-Shelf-IsoMesothelin-Gamma-Delta-CAR-T-cell-Therapy-30-Days-Before-the-End-of-the-Second-Quarter"
webUrl: "https://www.businesswire.com/news/home/20210524005256/en/Kiromic-Announces-FDA-IND-Submission-First-In-Human-AI-derived-Off-The-Shelf-IsoMesothelin-Gamma-Delta-CAR-T-cell-Therapy-30-Days-Before-the-End-of-the-Second-Quarter"
type: article

provider:
  name: Business Wire
  domain: businesswire.com

topics:
  - AI in Healthcare
  - AI

secured: "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;kqtBvu17NfGOefr7ZAzdGw=="
---

